Next Phase Newsletter

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Bright-eyed entrepreneurs with big ideas and even bigger fundraising needs have joined Digital RESI throughout 2021 in hopes of meeting investors who are just as excited to meet them, and there’s no virtual meeting spot that brings the two together like the Innovator’s Pitch Challenge (IPC). Apply to pitch at DIgital RESI November by October 22!

The IPC provides opportunities for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Fundraising entrepreneurs use the IPC for exposure, connection, valuable feedback, and often, a conversation that leads to many more down the road. Investors use it for the same – the opportunity to hear from and connect with entrepreneurs, learn more about exciting technology, and advance deal-flow initiatives.

For these reasons, the IPC is one of the most popular and well-attended features of the Digital RESI conference series, but don’t take our word for it. See what investors have said about their participation and check out previous investors that have sat on IPC judging panels throughout 2021.

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.” William Kuziel, MedPro Investors “The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.” Mayank Taneja, OSF Healthcare “I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.” Nat Brinn, VC23 “The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.” Gary Gershony, Life Science Angels / BayMed Venture Partners

Hamzeh Abdul-Hadi Hikma Ventures	Aiden Aceves Vida Ventures	Nuno Afonso Apogee Ventures	Brent Ahrens Canaan Partners
Alexandra Amen BridgeBio	Richard Anders Mass Medical Angels	Bauke Anninga M Ventures	Marc Appel Orange Grove Bio
Anjan Aralihalli CTI Life Sciences Fund	Aimee Barkway Hadean Ventures	Amine Benmoussa Apogee Ventures	Attila Berces FastVentures
Sascha Berger TVM Capital Life Science	Randy Berholtz Mesa Verde Venture Partners	Reetika Bhardwaj ARCH Venture Partners	Ivneet Bhullar Fusion Fund
Yoann Bonnamour Mérieux Equity Partners	Todd Brady Brace Pharma Capital	Nat Brinn VC23	Ivan Burkov INKEF Capital
Cynthia Cai Viva BioInnovator	Valerie Calenda Mérieux Equity Partners	Anke Cassing High-Tech Gründerfonds	Jeremy Chang BridgeBio
Benjamin Chen Panacea Ventures	Kenneth Chew Vickers Venture Partners	Poh Hui Chia Vickers Venture Partners	Chinmay Chinmay BioIdeations
Elizabeth Cho-Fertikh Meda Angels	Michel Chu Acorn Campus Taiwan	Pablo Cironi Caixa Capital Risc	Barbara Clarke Astia Angels
Darren Cooke Life Science Angels	Peter Crane Outsized Ventures	David Crean Mesa Verde Venture Partners	Ruchi Dana Dana Group
Aldemar Degroot Biogen	Niels Emmerich AbbVie Inc.	Bettina Ernst BERNINA BioInvest	Jemima Escamilla Research Corporation Technologies
Naomi Fried Ambit Health Ventures	Ryo Fujinami Shinsei Capital Partners	Robert Garber 7wire Ventures	Gary Gershony BayMed Venture Partners
Tom Gibbs Debiopharm Innovation Fund	Sam Goldberger Ambit Health Ventures	Gage Greening Medical Technology Enterprise Consortium (MTEC)	Bryan Grulke Volcano Capital
Brian Hakim MedtecX	Elaine Hamm Ascend BioVentures	Z Haroon Julz Co LLC	Christopher Haskell, Ph.D. Bayer
Michelle Ho 5AM Ventures	Vivien Ho Pear Ventures	Alan Hochberg Roche	Dave Hood Medical Technology Enterprise Consortium (MTEC)
Dmitrij Hristodorov Forbion Capital Partners	Adam Hunke Banner Venture Group	Tomoko Ishikura Kicker Ventures	Mishael Zohar OrbiMed Advisors LLC
I-Chien Jan Hukui Bio	Allan Johnston Synergy Ventures	Rick Jones BioAdvance	Patrick Keenan Prevail Partners
Faisal Khan AstraZeneca	John Kim Aphelion Capital, LLC	Kristin King Boston Harbor Angels	Merom Klein Keiretsu Forum
Pascal Krotee RiverVest Venture Partners	Dmitry Kuzmin 4Bio Capital Partners	Sebastien Latapie Dynamk Capital	Zachary Leach Catalyst Health Ventures
Carla Lema Tomé Otsuka Pharmaceutical	Elliot Levy DreamIt Health	George Li Proxima Ventures	Yatong Li Sixty Degree Capital
Xinhong Lim Vickers Venture Partners	Debbie Lin Boehringer Ingelheim Venture Fund	Don Lin Guoqian Venture Capital Investment	Henry Lu China Merchants Capital
Benedikt Luhmann VI Partners	Marc Martin-Casas Illumina Accelerator	Tai Mei Meda Angels	Andy Merken Burns & Levinson
Wouter Meuleman Illumina Ventures	Junaid Mian SP8CEVC	Sergio Montero Start-Up Chile	Walter Moos Pandect Bioventures
Anesa Mulabecirovic Hadean Ventures	Kim Nearing BVCF	Justin Norden GSR Ventures	Cédric Odje Debiopharm Innovation Fund
Michael O’Donnell Life Science Angels	Marion Paolini Servier	Nami Park Life Science Angels	Francoise Perron-Sierra Servier
Dave Pinkowitz AnPac Bio	Rohit Pratap Singh Xeraya Capital	Mark Ralph Boehringer Ingelheim Venture Fund	Varun Ramdevan Johnson & Johnson Innovation
David Ramos iGan Partners	Richard Reschen MSD	Stella Robertson Bios Partners	Mel Rothberg Mira Life Science Ventures
Nikhil Sadhwani Individual Angel	Caroline Sai Angels Santé	Christina Salys Intuitive Surgical	Diana Saraceni Panakes Partners
Barbara Schilberg BioAdvance	Steve Seuntjens Personal Health Solutions	Bryan Shao Keiretsu Forum	Niels Sharman High-Tech Gründerfonds
Megan Shaw Innovation Works	David Siet Amzak Health	Mira Sirotic Keiretsu Forum	Catello Somma TVM Capital Life Science
Jill Sorensen Medical Technology Enterprise Consortium (MTEC)	Adarsh Sowcar NOVA	Karen Spilizewski RiverVest Venture Partners	Mark Springel Vida Ventures
Sanjay Srinivasan Accent Advisors	Eran Steinberg Imaging Arts	Kevin Sterling Keiretsu Forum	Weiyong Sun Daiichi Sankyo
Ben Sun Sand Hill Angels	Haolin Sung Chaperone Investment	Gayathri Swaminath GreenFire Bio, LLC	Mayank Taneja OSF Healthcare Ventures
Mark Tang Good Health Capital	Liz Todia Mutual Capital Partners	Gadi Toren Robert Bosch Venture Capital	Bill Trainor Mutual Capital Partners
Robert Tucci Texas Halo Fund	Thomas Vogelsong KYTO Technology and Life Science	Tad Weems Agilent Technologies	Scott Weiner Amzak Health
Travis Whitfill Bios Partners	Thierry Wurch Ipsen S.A.	Jonathan Yeh Saisei Ventures	John Yianni Earlybird
Alicia Yin 6 Dimensions Capital	Derek Yuan LYFE Capital	Yanxiang Zhou Illumina Ventures	Anthony Zlaket UnityPoint Health Ventures

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Since going digital in 2020, RESI conferences have been able to grow and meet the unique needs of virtual partnering in many ways, but few more exciting than the Innovator’s Pitch Challenge (IPC). The IPC is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a $500 pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

Applications are due October 22, but those who apply by October 8 save an additional $200 with super early bird registration rates. Hear from past participants about their experiences pitching at RESI conferences and how their experiences contributed to their global fundraising efforts.

• Jonathan Cohen, 20/20 Gene Systems
• Andrea Wang, AHEAD Medicine
• Marc Rippen, Alertgy
• Michael Simon, Creative Bio-Peptides
• Buddy Lyons, Entac Medical
• Beth Sanders, LifeBio
• Anthony Desir, Moexa
• Edison Hudson, Panacea BioMatx
• Pepper Landson, Praetego
• Richard Austin, Reglagene

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Thanks to the support and enthusiasm from the RESI community, another week of early-stage life science and healthcare partnering and innovation is in the books! We are excited to announce our last event of the year, RESI Partnering Week November, which will be a robust 3-day partnering conference, November 16-18.

Registration is now open featuring Super Early Bird rates until Friday, October 8. Innovator’s Pitch Challenge (IPC) applications are also open, giving companies a platform to present their technology to hundreds of RESI attendees. If your early-stage company is fundraising, you do not want to miss out on these discounted rates and unique presentation opportunities.

Looking for more ways to get involved? Check out sponsorship offerings and learn more about how you can boost your exposure to the RESI network and optimize your experience and connections!

By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN) has successfully concluded the 3-Day Digital Redefining Early Stage Investment (RESI) conference. One of the highlights at the conference was the Innovator’s Pitch Challenge (IPC), an opportunity for early-stage companies to pitch live to a panel of investors and industry experts. Nearly 50 companies were featured at this past IPC and over 60 investors and industry experts have participated.

During the 3-Day RESI, each company was featured on a dedicated landing page that hosted their pitch video and supplementary materials. They also participated in a live Q&A session with a panel of judges, who are active investors or industry experts in the space. We were happy to see that the live Q&A sessions have attracted attendees from around the world, many of whom cast a vote for their favorite pitches.

Congratulations to the winners who will receive complimentary tickets to future RESI conferences, and many thanks to all the IPC finalists for their hard work preparing for the event, and to the pitch judges who supported each session with their great feedback. We hope to continue the IPC as a unique opportunity to create conversations between early-stage companies and investors, and we look forward to working with other innovative companies at future events!

1st Place – Cosm Medical

Cosm is bringing personalized medical devices to women suffering from pelvic floor disorders, a common, growing and stigmatized global women’s health issue. Through a seamless digital platform that combines proprietary diagnostics, AI, cloud software, and 3D printing, Cosm is commercializing the world’s first patient-specific pessary, Gynethotics. Our aim is to improve the clinician and patient experience while allowing more women to live and age with dignity and grace.

2nd Place – Ciscovery Bio

Ciscovery Bio is a genomics company that enables cis-regulatory modules (CRMs) such as enhancers and promoters for drug development, precision medicine, and biotechnology. Our CRM-based approach empowers (1) screening drugs at the preclinical stage, (2) mapping the genome-drug relationship, (3) developing a novel therapeutic application of existing drugs, and (4) precise expression of transgenes in gene therapy and in Ag biotech. This will bring saving of millions of dollars in drug development, more patient-centric drug treatment, and improvement in gene therapy and GM crops.

3rd Place – Celero Systems

Celero Systems has developed a long-acting physiological monitoring and drug delivery capsule. The smart capsule covers a range of enabling technologies including the ability to monitor physiology from inside the GI tract of a patient, and to respond to the detected physiology to treat a range of medical conditions. The capsule resides within the upper GI for a week and is cloud enabled allowing for physiological data to be shared with physicians resulting in improved patient care.